BioTissue Introduces CAM360 AmnioGraft Regenerative Therapy for Dry Eye and Ocular Surface Disorders
BioTissue has launched the CAM360 AmnioGraft (CAM360 AG), a new, hydrated, shelf-stable 'Cryopreserved Amniotic Membrane' (CAM) solution for dry eye and other ocular surface disorders. The company has begun initial shipments of the product, with nationwide availability expected by the end of the month.
Best suited for patients who have mild to moderate dry eye disease and other ocular surface conditions, CAM360 AG is a ringless CAM that does not require refrigeration. Its adhesive properties[1] ensure that the CAM stays in place under a Bandage Contact Lens (BCL), designed to increase patient comfort and treatment efficacy.
“The introduction of CAM360 AG revolutionizes how eye care professionals can leverage regenerative medicine in the treatment of the ocular surface, particularly when it comes to dry eye disease,” Ted Davis, President and CEO, BioTissue, said in a company news release. “Dry eye disease is a progressive disease, and until now, the lack of options available meant that practitioners often had to wait until the patient’s condition worsened before they could intervene. CAM360 AG bridges that gap, enabling practitioners to provide more patients with treatment much earlier, which is a true reflection of our dedication to improving patients’ lives with everything we do.”
CAM's unique composition exerts anti-inflammatory, anti-scarring, and anti-angiogenic actions that help promote the body’s healing capabilities. [2,3,4] It is adaptable to treat many conditions including mild to moderate dry eye disease, superficial punctate keratitis, neurotrophic keratitis, and more, according to BioTissue.
BioTissue’s proprietary CryoTek and SteriTek preservation methods are the only proven processing methods that retain the HC-HA/PTX3 found in fresh tissue, which is, in part, responsible for amniotic membrane’s therapeutic benefits.[5] These processes were specifically designed to optimize preservation while providing efficiencies in handling, storage, and product application.
BioTissue has provided treatment to more than 800,000 patients, with its scientific and clinical breakthroughs documented in more than 390 peer-reviewed publications. BioTissue is aiming to address unmet needs in the ocular, orthopedic, and wound management markets.
For more information about BioTissue and CAM360 AG, visit BioTissue.com/ocular.
References
1 BioTissue, Data on File, 2024.
2 John, T., Tighe, S., Sheha, H., Hamrah, P., Salem, Z. M., Cheng, A., ... & Rock, N. D.(2017). Corneal nerve regeneration after self-retained cryopreserved amniotic membrane in dry eye disease. Journal of Ophthalmology, 2017.
3 McDonald, M. B., Sheha, H., Tighe, S., Janik, S. B., Bowden, F. W., Chokshi, A. R., ... & McMurren, B. J. (2018). Treatment outcomes in the dry eye amniotic membrane (DREAM) study. Clinical Ophthalmology, 677-681.
4 Cheng, A. M., Zhao, D., Chen, R., Yin, H. Y., Tighe, S., Sheha, H., ... & Tseng, S. C.(2016). Accelerated restoration of ocular surface health in dry eye disease by self-retained cryopreserved amniotic membrane. The Ocular Surface, 14(1), 56-63.
5 Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SC. J Wound Care. 2014;23(10):465-476.